Vogenx (NASDAQ:VOGX – Get Free Report) was upgraded by stock analysts at JonesTrading to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks reports.
Separately, Wall Street Zen upgraded Vogenx to a “hold” rating in a report on Saturday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, Vogenx has an average rating of “Strong Buy” and an average target price of $55.00.
Check Out Our Latest Analysis on Vogenx
Vogenx Trading Down 2.6%
About Vogenx
Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.
Recommended Stories
- Five stocks we like better than Vogenx
- Will the Most Successful Quantum Firms Be Software Companies?
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.
